Background: Cardiac Implantable Electronic Devices (CIED) include pulse
generators and leads. In some implanting centres, it is common practice
to combine devices with leads from different companies. Case series have
reported episodic high-impedance changes in Boston Scientific CIEDs with
competitor leads. We investigated the incidence of high-impedance
abnormalities in matched vs. mismatched Boston Scientific CIEDs.
Methods: Retrospective chart review identified all consecutive Boston
Scientific Accolade pacemakers and Autogen implantable cardioverter
defibrillators (ICD) implanted between January 2017 and June 2019 at a
Canadian tertiary care centre. The primary outcome was the occurrence of
transient, high-impedance changes which resulted in a switch to unipolar
pacing / sensing in the absence of any other identifiable lead issue.
Fisher exact tests (two-tailed, α = 0.05) were used to compare the
incidence of outcomes in matched vs. mismatched systems. Results: 564
Boston Scientific CIEDs were identified associated with 969 individual
leads. The primary outcome occurred with 22 leads (21 Medtronic and 1
Abbott), associated with occasional pacing inhibition, syncope, and/or
early surgical revision. Mismatched systems were significantly
associated with CIED malfunction compared to matched systems (3.4% vs.
0%, P = 0.0001). Median time from implant to unipolar safety switch was
19.3 months. Median follow-up time was 21.6 months. Conclusion: Use of
mismatched leads with a Boston Scientific Accolade or Autogen device was
associated with increased system malfunction and adverse clinical
outcomes. Awareness of this interaction can allow for institution of
appropriate programming remedies and may increase scrutiny of the use of
mismatched CIED systems.